Payment overview · 2025
General Payments
$1,978.35
53 reported records · 18 companies
Healthcare provider profile · identity verified
Brian Ignatius Rebello, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DELRAY BEACH, FL · NPI 1497728877
Verified facts
What the public records show
CMS Open Payments records show Brian Ignatius Rebello, M.D. received $1,978.35 in general payments during 2025 across 53 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Prolia, Rexulti, Rybelsus, Synthroid, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $404.39 | 20.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.72 | 12.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $214.43 | 10.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.33 | 10.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $181.93 | 9.2% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $118.77 | 6.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $117.87 | 6.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $85.77 | 4.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.72 | 3.9% | 4 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $65.52 | 3.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $58.54 | 3.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $50.23 | 2.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.80 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.34 | 2.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.02 | 1.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.15 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.85 | 0.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $14.97 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,978.35 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $404.39 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $239.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $180.25 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.00 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $148.35 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $117.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $117.87 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $85.77 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $65.52 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $65.52 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $58.54 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $50.23 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.15 | 3 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $44.80 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.74 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 201 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 184 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
184 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
201 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
208 | 69 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1268 | 378 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1055 | 298 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1019 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 956 | 285 |
| Alprazolam | Alprazolam | 706 | 198 |
| Losartan Potassium | Losartan Potassium | 689 | 201 |
| Omeprazole | Omeprazole | 433 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 140 |
| Escitalopram Oxalate | Escitalopram Oxalate | 380 | 112 |
| Azithromycin | Azithromycin | 371 | 294 |
| Gabapentin | Gabapentin | 364 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 107 |
| Methylprednisolone | Methylprednisolone | 333 | 263 |
| Simvastatin | Simvastatin | 314 | 94 |
| Lisinopril | Lisinopril | 305 | 90 |
| Famotidine | Famotidine | 295 | 111 |
| Metformin Hcl | Metformin Hcl | 293 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 256 | 104 |
| Sertraline Hcl | Sertraline Hcl | 249 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 85 |
| Trazodone Hcl | Trazodone Hcl | 246 | 86 |
| Potassium Chloride | Potassium Chloride | 244 | 83 |
| Furosemide | Furosemide | 231 | 86 |
| Montelukast Sodium | Montelukast Sodium | 222 | 68 |
| Eliquis | Apixaban | 208 | 69 |
| Tramadol Hcl | Tramadol Hcl | 205 | 73 |
| Ozempic | Semaglutide | 201 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 64 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 196 | 158 |
| Allopurinol | Allopurinol | 192 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 52 |
| Repaglinide | Repaglinide | 184 | 64 |
| Synthroid | Levothyroxine Sodium | 184 | 51 |
| Carvedilol | Carvedilol | 183 | 57 |
| Temazepam | Temazepam | 179 | 52 |
| Ezetimibe | Ezetimibe | 171 | 54 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 161 | 127 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 151 | 50 |
| Ipratropium Bromide | Ipratropium Bromide | 146 | 89 |
| Diazepam | Diazepam | 138 | 46 |
| Lorazepam | Lorazepam | 134 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 47 |
| Finasteride | Finasteride | 121 | 42 |
| Buspirone Hcl | Buspirone Hcl | 119 | 39 |
| Repatha Sureclick | Evolocumab | 118 | 19 |
| Valsartan | Valsartan | 117 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 109 | 34 |
| Donepezil Hcl | Donepezil Hcl | 108 | 31 |
| Prednisone | Prednisone | 106 | 73 |
| Clonazepam | Clonazepam | 104 | 31 |
| Atenolol | Atenolol | 101 | 30 |
| Mirtazapine | Mirtazapine | 93 | 32 |
| Spironolactone | Spironolactone | 92 | 36 |
| Jardiance | Empagliflozin | 86 | 23 |
| Alendronate Sodium | Alendronate Sodium | 84 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 26 |
| Memantine Hcl | Memantine Hcl | 78 | 26 |
| Xarelto | Rivaroxaban | 78 | 23 |
| Meloxicam | Meloxicam | 77 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 35 |
| Telmisartan | Telmisartan | 76 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 28 |
| Glipizide | Glipizide | 72 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 71 | 17 |
| Pregabalin | Pregabalin | 67 | 29 |
| Glimepiride | Glimepiride | 65 | 23 |
| Ramipril | Ramipril | 64 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 17 |
| Labetalol Hcl | Labetalol Hcl | 63 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 17 |
| Midodrine Hcl | Midodrine Hcl | 58 | 26 |
| Cephalexin | Cephalexin | 56 | 48 |
| Enalapril Maleate | Enalapril Maleate | 56 | 16 |
| Bumetanide | Bumetanide | 55 | 29 |
| Mounjaro | Tirzepatide | 54 | 12 |
| Meclizine Hcl | Meclizine Hcl | 53 | 28 |
| Rybelsus | Semaglutide | 53 | 15 |
| Topiramate | Topiramate | 53 | 16 |
| Bupropion Xl | Bupropion Hcl | 52 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Januvia | Sitagliptin Phosphate | 52 | 14 |
| Warfarin Sodium | Warfarin Sodium | 52 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Celecoxib | Celecoxib | 48 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 12 |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 30 |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 11 |
| Valacyclovir | Valacyclovir Hcl | 40 | 20 |
| Levetiracetam | Levetiracetam | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 30 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 18 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 35 | 14 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 34 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Nystatin | Nystatin | 24 | 17 |
| Ondansetron Odt | Ondansetron | 24 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 20 |
| Estradiol | Estradiol | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Risperidone | Risperidone | 21 | suppressed |
| Tadalafil | Tadalafil | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Valproic Acid | Valproic Acid | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 11 |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Clarithromycin | Clarithromycin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Metaxalone | Metaxalone | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Unithroid | Levothyroxine Sodium | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Brilinta | Ticagrelor | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,978.35 · 53 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, EVENITY, Flexitouch Plus, GEMTESA, JARDIANCE, KEVEYIS, KISUNLA, Korlym, LEQVIO, LOREEV XR, Leqembi, MOUNJARO, Nimbl, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, UBRELVY, Wegovy, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error